InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,522.40
(
0.59%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.64
(
-0.07%
)
Bitcoin
65,650.17
(
1.05%
)
Post# of 252255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119875
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: orangeone post# 134252

Tuesday, 01/03/2012 6:35:20 PM

Tuesday, January 03, 2012 6:35:20 PM

Post# of 252255
Most of ARNA’s CC was about new analysis of the rat-carcinogenicity data. VP of clinical development, Christy Anderson seemed well prepared for the questions from the apparently skeptical questioners, especially when elaborating on the two distinct pathways for pathogenesis of rat mammary tumors.

Whether this makes ARNA a compelling buy at an enterprise value of roughly $300M is unclear. My cursory answer is no, but I’d be somewhat more inclined to take a flier after today’s news than I would have been previously, even after accounting for the double-digit price gain in the AH session.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up